Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CRISPR screen identifies genes that sensitize AML cells to double negative T cell therapy [guide RNA]

ABSTRACT: CRISPR screen identifies genes that sensitize AML cells to double negative T cell therapy [guide RNA]

PROVIDER: PRJNA661568 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12594400.fastq.gz	Fastqsanger.gz
	SRR12594401.fastq.gz	Fastqsanger.gz
	SRR12594402.fastq.gz	Fastqsanger.gz
	SRR12594403.fastq.gz	Fastqsanger.gz
	SRR12594404.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 28

Similar Datasets

CRISPR screen identifies genes that sensitize AML cells to double negative T cell therapy

Project description:CRISPR screen identifies genes that sensitize AML cells to double negative T cell therapy

| PRJNA662233 | ENA

CRISPR screen identifies genes that sensitize AML cells to double negative T cell therapy [guide RNA]

Project description:Here, we used a targeted CRISPR/Cas9 screen to identify genes that confer susceptibility of AML cells to DNT cell therapy.

2020-12-14 | GSE157527 | GEO

CRISPR screen identifies genes that sensitize AML cells to double negative T cell therapy [RNA-Seq]

Project description:CRISPR screen identifies genes that sensitize AML cells to double negative T cell therapy [RNA-Seq]

| PRJNA662239 | ENA

CRISPR screen identifies genes that sensitize AML cells to double negative T cell therapy [RNA-Seq]

Project description:Here, we used a targeted CRISPR/Cas9 screen to identify genes that confer susceptibility of AML cells to DNT cell therapy.

2020-12-14 | GSE157617 | GEO

Genome wide CRISPR screen in AML chemotherapy resistance.

Project description:Genome wide CRISPR screen in AML chemotherapy resistance.

| PRJNA986910 | ENA

CRISPR screen identifies genes that sensitize AML cells to double negative T cell therapy

Project description:This SuperSeries is composed of the SubSeries listed below.

2020-12-14 | GSE157618 | GEO

DNA double strand breaks in KMT2A-rearranged AML patients

Project description:DNA double strand breaks in KMT2A-rearranged AML patients

| PRJNA805340 | ENA

DNA double strand breaks in KMT2A-rearranged AML patients

Project description:DNA double strand breaks in KMT2A-rearranged AML patients

| PRJNA805339 | ENA

A kinome-wide CRISPR screen identifies CK1α as a novel target to overcome enzalutamide resistance of prostate cancer

Project description:Utilizing a kinome-wide CRISPR-Cas9 knockout screen, we identified casein kinase 1 alpha (CK1α) as a novel therapeutic target to overcome enzalutamide resistance. To dissect the underlying mechanisms of targeting CK1α to sensitize cancer cells to ENZA, we performed RNA sequencing of 22Rv1 cells upon CK1α knockout or overexpression. We found that CK1α regulated double-strand break (DSB)-response signaling.

2023-03-10 | GSE203362 | GEO

Transcription profiling of human newly diagnosed AML CEBPA double and single mutant and CEBPA wild type AML.

Project description:Mutations in CCAAT/enhancer binding protein alpha (CEBPA) are seen in 5-14% of acute myeloid leukemia (AML) and have been associated with a favorable clinical outcome. Most AMLs with CEBPA mutations simultaneously carry two mutations (CEBPAdouble-mut), usually biallelic, while single heterozygous mutations (CEBPAsingle-mut) are less frequently seen. Using denaturing high performance liquid chromatography and nucleotide sequencing we identified among a cohort of 598 newly diagnosed AMLs a subset of 41 CEBPA mutant cases, i.e. 28 CEBPAdouble-mut and 13 CEBPAsingle-mut cases. CEBPAdouble-mut associated with a unique gene expression profile as well as favorable overall and event-free survival, retained in multivariable analysis that included cytogenetic risk, FLT3-ITD and NPM1 mutation, white blood cell count and age. In contrast, CEBPAsingle-mut AMLs did not express a discriminating signature and could not be distinguished from wild type cases as regards clinical outcome. These results demonstrate significant underlying heterogeneity within CEBPA mutation positive AML with prognostic relevance. Experiment Overall Design: Gene expression profiling of 524 cases of de novo AML. Comparisons of cases with double and single CEBPA mutations versus those with wild type CEBPA.

2009-01-23 | E-GEOD-14468 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data